Skip to content
Canada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-only
Journal

Research news

Obesity peptides at a rheumatology meeting.What ACR 2026 showed.

Retatrutide knee osteoarthritis data and week 52 tirzepatide results in psoriatic arthritis, summarized from what the developer reported this week.

By Proof Line Peptides · Published · 4 min read

GLP-3 10 mg labelled research vial

Two incretin-class peptides showed up this week at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, held November 6 to 11 in Orlando. The data looked at joints, not just weight.

This is a summary of what the developer reported. It is not guidance of any kind.

Why a rheumatology meeting

The developer's announcement cites estimates that about 80% of people with knee osteoarthritis have obesity or overweight. It also cites real-world data suggesting about 65% of U.S. patients with psoriatic arthritis have obesity or overweight plus at least one weight-related condition. The research question is whether reducing body weight with these compounds changes joint outcomes, and by how much.

TRIUMPH-4: retatrutide and knee osteoarthritis

Retatrutide acts on three receptors: GLP-1, GIP and glucagon. Our earlier posts cover the TRIUMPH obesity trials and the head-to-head TRANSCEND-T2D-2 trial. TRIUMPH-4 was presented as a plenary on November 8.

Design

  • Phase 3, randomized, double-blind, placebo-controlled, 68 weeks.
  • 445 adults with obesity or overweight and knee osteoarthritis, without diabetes.
  • 84% had a baseline BMI of 35 or higher.
  • Two active study arms and one placebo arm, randomized 1:1:1.

Reported outcomes at 68 weeks (efficacy estimand)

  • Weight fell by 26.4% and 28.7% in the two active arms, versus 2.1% with placebo.
  • On the WOMAC pain subscale, from a baseline of 6.0 points, scores fell by 4.5 and 4.4 points in the active arms.
  • That is a reduction of about 75.8% and 74.3%, versus 40.3% with placebo.
  • More than 1 in 8 participants in the active arms reported no knee pain at the end of the trial.

The developer notes that the pain and physical function analyses were post hoc, not pre-specified. That limits how firmly the pain numbers can be read.

Tolerability

  • Nausea, diarrhea, constipation and vomiting were the most common adverse events.
  • Dysesthesia, an altered skin sensation, was reported in 8.8% and 20.9% of the active arms, versus 0.7% with placebo.
  • Discontinuation for adverse events was 12.2% and 18.2% in the active arms, versus 4.0% with placebo.

TRIUMPH-1: the knee osteoarthritis group

A poster on November 10 looked at participants with knee osteoarthritis and obesity in the 80-week TRIUMPH-1 trial. It compared three active study arms with placebo.

  • WOMAC pain fell by up to 4.3 points, about 73.1%, from a baseline of 6.0.
  • More than 1 in 6 participants in the active arms reported no knee pain at the end of the trial.
  • As with TRIUMPH-4, the percent change in pain was a post hoc analysis.

TOGETHER-PsA: tirzepatide alongside ixekizumab

Tirzepatide acts on two receptors, GLP-1 and GIP. For background on the receptor names, see GLP-1, GIP and glucagon: understanding receptor names.

TOGETHER-PsA tested whether adding tirzepatide to ixekizumab, an approved IL-17A antibody, changed outcomes in psoriatic arthritis.

Design

  • Phase 3b, randomized, open-label with blinded assessors, 52 weeks.
  • 271 adults with active psoriatic arthritis and obesity or overweight.
  • One study arm received ixekizumab alone, the other ixekizumab plus tirzepatide.
  • Both arms received diet and activity counselling.

What was reported earlier in 2026, at week 36

  • The primary endpoint combined a 50% improvement in arthritis signs (ACR50) with at least 10% weight reduction.
  • 31.7% of the combination arm met it, versus 0.8% of the ixekizumab-only arm.
  • ACR50 alone was reached by 33.5% versus 20.4%.

What is new at ACR 2026, at week 52

  • ACR50 was reached by 43.7% of the combination arm, versus 15.7% with ixekizumab alone.
  • The developer describes the week 52 analyses as pre-specified but exploratory, without multiplicity control.
  • Comparisons across timepoints are descriptive and were not statistically tested.

The full week 52 oral presentation is scheduled for November 11.

How to read these results

All of these figures come from company announcements and conference abstracts. Full peer-reviewed papers for the week 52 and knee osteoarthritis analyses were not yet available at the time of writing. Two points deserve attention.

  • The knee pain results are post hoc, so they generate hypotheses rather than confirm them.
  • TOGETHER-PsA was open-label, which can influence patient-reported measures.

For a framework on reading trials like these, see Reading a peptide study: population, comparator, endpoint and follow-up.

Sources

For laboratory research use only. Not for human or veterinary use.

Shop the vials

Proof Line offers by email.

For laboratory research use only. Not for human or veterinary use.